Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 34Completed 14Unknown 8Active not recruiting 7Not yet recruiting 6Withdrawn 3Terminated 3Enrolling by invitation 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Solid Tumor 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × toripalimab × Clear all
NCT06105008 2024-08-23

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

RemeGen Co., Ltd.

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT05212922 2023-03-20

YH001

Eucure (Beijing) Biopharma Co., Ltd

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05165849 2022-05-20

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Genfleet Therapeutics (Shanghai) Inc.

Phase 1/2 Withdrawn
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡